Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
Lisa A. Beck(University of Rochester Medicine), Ana B. Rossi(Sanofi (United States)), Michael J. Cork(Royal Hallamshire Hospital), Anna De Benedetto(University of Rochester Medicine), Masayuki Amagai(Keio University), Jennifer D. Hamilton(Regeneron (United States)), Kenji Kabashima(Kyoto University)
Cited by 234
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k